The FDA has approved Lumipulse, the first blood test for diagnosing Alzheimer’s, offering a simpler and less invasive option compared to traditional methods like PET scans. Experts believe this could revolutionize care and research.
The FDA has approved a groundbreaking blood test, Lumipulse, that detects amyloid plaques linked to Alzheimer’s disease, offering a safer, more accessible diagnostic tool for millions.
